Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...
Investing News Network on MSN

Moderna to pay US$950 million to settle COVID-19 vaccine patent dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.
BioPharma Dive

Moderna to pay up to $2.25B to end mRNA vaccine patent fight

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.
IPWatchdog

Moderna Settles with Genevant and Arbutus, Ending LNP Patent Dispute

In a press release issued on Tuesday, Genevant Sciences and Arbutus Biopharma announced they have entered into a global settlement with Moderna, Inc. that could result in a payment of up to $2.5 ...

European health agency recommends approving Moderna’s combined flu, COVID vaccine

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...
STAT

I was a Moderna exec when the Covid vaccine rolled out. That spirit of possibility is no more

Hughes is a partner with the law firm Epstein Becker Green and a professorial lecturer in law at the George Washington University Law School. He previously served as vice president of public policy at ...